lincomycin has been researched along with flucytosine in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Hermans, PE; Wilkowske, CJ | 1 |
1 review(s) available for lincomycin and flucytosine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for lincomycin and flucytosine
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Septicaemia.
Topics: Cefazolin; Cephaloridine; Cephalothin; Cephradine; Clindamycin; Drug Resistance, Microbial; Flucytosine; Gentamicins; Humans; Lincomycin; Metronidazole; Sepsis; Shock, Septic; Tobramycin | 1975 |
Actions and uses of antimicrobial agents in the treatment of musculoskeletal infections.
Topics: Aminoglycosides; Amphotericin B; Anti-Bacterial Agents; Bone Diseases; Cephalosporins; Chloramphenicol; Clindamycin; Erythromycin; Flucytosine; Humans; Infections; Lincomycin; Muscular Diseases; Nystatin; Penicillins; Tetracyclines | 1975 |